First Community Trust NA Lowers Position in Kenvue Inc. (NYSE:KVUE)

First Community Trust NA reduced its stake in Kenvue Inc. (NYSE:KVUE) by 8.8% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 7,696 shares of the company’s stock after selling 738 shares during the period. First Community Trust NA’s holdings in Kenvue were worth $178,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of the stock. Price T Rowe Associates Inc. MD boosted its position in shares of Kenvue by 23.1% during the first quarter. Price T Rowe Associates Inc. MD now owns 134,565,333 shares of the company’s stock worth $2,887,773,000 after buying an additional 25,238,112 shares during the period. Vanguard Group Inc. grew its position in Kenvue by 12.0% in the 1st quarter. Vanguard Group Inc. now owns 166,789,085 shares of the company’s stock valued at $3,579,294,000 after acquiring an additional 17,908,497 shares in the last quarter. Van ECK Associates Corp grew its position in Kenvue by 110.9% in the 2nd quarter. Van ECK Associates Corp now owns 20,510,427 shares of the company’s stock valued at $372,880,000 after acquiring an additional 10,783,258 shares in the last quarter. Clearbridge Investments LLC increased its stake in Kenvue by 16,051.1% during the first quarter. Clearbridge Investments LLC now owns 9,813,597 shares of the company’s stock worth $210,600,000 after purchasing an additional 9,752,836 shares during the period. Finally, Bank of New York Mellon Corp lifted its position in shares of Kenvue by 21.0% during the second quarter. Bank of New York Mellon Corp now owns 43,444,085 shares of the company’s stock worth $789,813,000 after purchasing an additional 7,546,362 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Stock Down 0.7 %

Shares of NYSE:KVUE opened at $22.63 on Thursday. The firm has a 50 day simple moving average of $21.69 and a 200-day simple moving average of $20.13. Kenvue Inc. has a twelve month low of $17.67 and a twelve month high of $23.55. The company has a current ratio of 0.99, a quick ratio of 0.68 and a debt-to-equity ratio of 0.69. The company has a market capitalization of $43.33 billion, a PE ratio of 29.01, a P/E/G ratio of 2.92 and a beta of 1.40.

Kenvue (NYSE:KVUE) last announced its quarterly earnings results on Tuesday, August 6th. The company reported $0.32 earnings per share for the quarter, beating analysts’ consensus estimates of $0.28 by $0.04. The firm had revenue of $4 billion during the quarter, compared to analysts’ expectations of $3.93 billion. Kenvue had a net margin of 7.23% and a return on equity of 21.80%. Kenvue’s quarterly revenue was down .3% compared to the same quarter last year. During the same period in the previous year, the company earned $0.32 earnings per share. On average, equities analysts predict that Kenvue Inc. will post 1.08 EPS for the current fiscal year.

Kenvue Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, August 28th. Investors of record on Wednesday, August 14th were paid a dividend of $0.205 per share. This represents a $0.82 dividend on an annualized basis and a yield of 3.62%. The ex-dividend date of this dividend was Wednesday, August 14th. This is an increase from Kenvue’s previous quarterly dividend of $0.20. Kenvue’s dividend payout ratio (DPR) is currently 105.13%.

Analysts Set New Price Targets

KVUE has been the topic of several recent research reports. Deutsche Bank Aktiengesellschaft upped their target price on shares of Kenvue from $23.00 to $24.00 and gave the stock a “buy” rating in a research note on Wednesday, August 7th. UBS Group increased their price objective on Kenvue from $20.00 to $22.00 and gave the company a “neutral” rating in a research note on Wednesday, August 7th. Citigroup lowered their target price on Kenvue from $21.00 to $20.00 and set a “neutral” rating for the company in a research note on Wednesday, July 10th. JPMorgan Chase & Co. increased their price target on Kenvue from $22.00 to $24.00 and gave the company an “overweight” rating in a research report on Wednesday, August 7th. Finally, Jefferies Financial Group began coverage on Kenvue in a research report on Tuesday, September 24th. They set a “buy” rating and a $27.00 price objective for the company. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $22.10.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.